Company Overview and News

2
ASX advances on bank strength as CSL breaks $200

2018-07-12 theage.com.au
The Australian sharemarket has closed higher despite an overnight commodity plunge that saw Brent crude prices record their biggest fall in two years.
WOPEF RIO BLT RIO OGFGY BEPTF RTPPF RTNTF TWE TSRYY BHPBF WTCHF WPL BCHEY WOPEY BPT TSRYF TNE BHP RIO BBL BHP OGFGF BHPLF ORG

2
ASX advances on bank strength as CSL breaks $200

2018-07-12 smh.com.au
The Australian sharemarket has closed higher despite an overnight commodity plunge that saw Brent crude prices record their biggest fall in two years.
WOPEF RIO BLT RIO OGFGY BEPTF RTPPF RTNTF TWE TSRYY BHPBF WTCHF WPL BCHEY WOPEY BPT TSRYF TNE BHP RIO BBL BHP OGFGF BHPLF ORG

2
Australian shares advance on strength of major banks

2018-07-03 theage.com.au
The Australian sharemarket has recorded only its second advance in the last eight sessions despite a broad retreat of commodity prices overnight.
PILBF RIO DB BLT RIO IAG MS.PRE MS.PRF MS.PRG MS.PRA BEPTF RTPPF GALXF RTNTF MS TWE SML IAUGY PLS TSRYY BHPBF EBOSY EBO BCHEY BPT EBOSF TSRYF GXY IAUGF MS.PRI BHP RIO MS.PRK BBL BHP BHPLF EBO

2
Australian shares advance on strength of major banks

2018-07-03 smh.com.au
The Australian sharemarket has recorded only its second advance in the last eight sessions despite a broad retreat of commodity prices overnight.
PILBF RIO DB BLT RIO IAG MS.PRE MS.PRF MS.PRG MS.PRA BEPTF RTPPF GALXF RTNTF MS TWE SML IAUGY PLS TSRYY BHPBF EBOSY EBO BCHEY BPT EBOSF TSRYF GXY IAUGF MS.PRI BHP RIO MS.PRK BBL BHP BHPLF EBO

0
Full-bodied move by Penfolds comes with risk

2018-07-03 theage.com.au
If Penfolds’ flagship Grange were made with grapes sourced from the Napa Valley would it still be regarded in the same revered light? That’s not quite the question Treasury Wine Estates is posing to wine connoisseurs but the decision to source Penfolds-branded products from outside Australia for the first time is a bold and potentially risky one.
TSRYY TSRYF TWE

0
Full-bodied move by Penfolds comes with risk

2018-07-03 smh.com.au
If Penfolds’ flagship Grange were made with grapes sourced from the Napa Valley would it still be regarded in the same revered light? That’s not quite the question Treasury Wine Estates is posing to wine connoisseurs but the decision to source Penfolds-branded products from outside Australia for the first time is a bold and potentially risky one.
TSRYY TSRYF TWE

3
Australia to pass foreign interference laws amid rising China tensions

2018-06-27 theedgemarkets
SYDNEY/BEIJING (June 27): Australia is expected to pass legislation on Thursday aimed at preventing interference by foreign governments, a move likely to further stoke tensions with major trading partner China.
TSRYY TSRYF TPGTF TPPTY TPM TWE

1
Australia to pass foreign interference bill amid tensions with China | Euronews

2018-06-27 euronews
SYDNEY (Reuters) – Australia is expected to pass new legislation on Wednesday aimed at preventing interference by foreign governments, a move likely to further stoke tensions with major trading partner China.
TSRYY TSRYF TWE RI

1
Australia to pass foreign interference bill amid tensions with China - Channel NewsAsia

2018-06-27 channelnewsasia
Australia is expected to pass new legislation on Wednesday aimed at preventing interference by foreign governments, a move likely to further stoke tensions with major trading partner China.
TSRYY TSRYF TWE RI

0
Chinese telco Huawei lobbies hard to allay Australia's security concerns

2018-06-27 channelnewsasia
Chinese telecom firm Huawei Technologies Co Ltd's network equipment is "safe and secure", its Australian chairman said on Wednesday, ramping up the company's public lobbying against concerns that its links to China pose a security risk.
TSRYY TSRYF TWE

0
Chinese telco Huawei lobbies hard to allay Australia's security concerns

2018-06-27 reuters
SYDNEY (Reuters) - Chinese telecom firm Huawei Technologies Co Ltd’s [HWL.UL] network equipment is “safe and secure”, its Australian chairman said on Wednesday, ramping up the company’s public lobbying against concerns that its links to China pose a security risk.
TSRYY TSRYF TWE

9
The Wine Industry In 20 Years: Will Blenders Be King?

2018-06-22 seekingalpha
1. Research has shown no correlation between price and the wines people like. From blind tastings in Paris (1976), Princeton (2012), Stellenbosch (2013), The Lenox Wine Club (2012-14), Lecocq and Visser, Goldstein et al, and Ashton, we have learned that “expert” and “amateur” drinkers do not prefer expensive wines to less expensive ones: there is no correlation between price and how people rate wines.
TSRYY VCO TSRYF GIS STZ TWE DEO

0
Chinese ambassador calls on Australia to drop 'Cold War mentality' | Euronews

2018-06-19 euronews
CANBERRA/SYDNEY (Reuters) – China’s ambassador to Australia said on Tuesday “less bias and bigotry” was needed to repair bilateral relations amid concerns over Chinese influence in Australia and its use of loans to build leverage over poorer South Pacific island nations.
TSRYY TSRYF TWE

0
Chinese ambassador calls on Australia to drop 'Cold War mentality'

2018-06-19 theedgemarkets
CANBERRA/SYDNEY (June 19): China's ambassador to Australia said on Tuesday "less bias and bigotry" was needed to repair bilateral relations amid concerns over Chinese influence in Australia and its use of loans to build leverage over poorer South Pacific island nations.
TSRYY TSRYF TWE

0
Chinese ambassador calls on Australia to drop 'Cold War mentality'

2018-06-19 channelnewsasia
CANBERRA/SYDNEY: China's ambassador to Australia said on Tuesday "less bias and bigotry" was needed to repair bilateral relations amid concerns over Chinese influence in Australia and its use of loans to build leverage over poorer South Pacific island nations.
TSRYY TSRYF TWE

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 89465J109